Pull to refresh
Logo
Merck's TROP2 drug posts first survival win in late-line stomach cancer

Merck's TROP2 drug posts first survival win in late-line stomach cancer

New Capabilities

TroFuse-015 met overall survival in 473 patients who had failed two prior regimens, but missed progression-free survival

Overview

Updated 2 hours ago

For patients whose stomach or esophageal cancer has spread and survived two chemotherapy regimens, few treatments still extend life. In a 473-patient Phase 3 trial, Merck's sacituzumab tirumotecan (sac-TMT) did: patients lived longer than those given physician's-choice chemotherapy, the first time a TROP2-directed antibody-drug conjugate has shown that in a global Phase 3 trial in this disease.

The win is not clean. TroFuse-015 missed its secondary progression-free survival endpoint, so the benefit appears in length of life rather than in time before tumors grow. Merck did not release the size of the survival gain or the hazard ratio, and said the data will be presented at an upcoming medical meeting and shared with regulators. It is the second positive Phase 3 for sac-TMT, which Merck licensed from China's Kelun-Biotech, after an endometrial cancer trial met both of its survival endpoints.

Why it matters

A survival benefit in third-line stomach cancer would give patients a drug class that has never proven it extends life in this disease.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

473
Patients randomized in TroFuse-015
Adults with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma after two or more prior regimens.
2
Positive Phase 3 readouts for sac-TMT
TroFuse-005 in endometrial cancer and TroFuse-015 in gastroesophageal cancer.
0.68
Hazard ratio for death in TroFuse-005
Endometrial cancer trial: median overall survival 19.0 versus 12.1 months on chemotherapy.
1st
TROP2 ADC with an OS win in this setting
No other TROP2-directed conjugate has shown an overall survival benefit in a global Phase 3 gastroesophageal trial.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

2024 November 2026

2 events Latest: Today
  1. TroFuse-015 meets overall survival endpoint

    Today Clinical result

    Merck reports a statistically significant survival improvement over chemotherapy; progression-free survival missed.

  2. TroFuse-015 design published

    Clinical trial

    Investigators outline a randomized Phase 3 of sac-TMT versus physician's-choice chemotherapy, with overall survival as the primary endpoint.

Scenarios

1

Merck files for gastroesophageal approval

Likely Resolves by Q3 2027

Discussed by: Merck, which said it will share the TroFuse-015 data with regulatory authorities

An overall survival benefit is the cleanest basis for a filing in a disease where patients have run out of options. If Merck's topline holds up in the full dataset, a submission to the FDA would follow, likely within months of the data presentation. A filing is the first hard signal that the company believes the result is approvable rather than merely positive.

2

FDA approves sac-TMT for third-line gastroesophageal cancer

Possible Resolves by End of 2028

Discussed by: RBC Capital Markets analysts, who wrote in a note reported by BioSpace that overall survival remains the standard in this setting

Approval would make sac-TMT the first TROP2-directed conjugate cleared for gastroesophageal adenocarcinoma. The missing progression-free survival endpoint complicates the label but does not block approval, since the FDA's primary question is whether patients lived longer. Timing depends on filing, priority review status, and whether the agency wants an advisory committee.

3

Full data show a survival benefit thinner than TroFuse-005's

Uncertain Resolves by Q2 2027

Discussed by: Oncologists and analysts working from a topline that disclosed no hazard ratio, median or confidence interval

The endometrial trial cut the risk of death by 32%. A gastroesophageal result closer to a hazard ratio of 0.85 would still be a regulatory win but a weaker commercial one, and payers could restrict access. The full presentation, expected at a medical meeting, is where that becomes knowable.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2017-2021

Keytruda's withdrawn third-line gastric approval (2017-2021)

The FDA granted Merck accelerated approval in 2017 for Keytruda in recurrent gastric or gastroesophageal junction cancer after two prior therapies, based on how much tumors shrank rather than on survival. Confirmatory trials in earlier lines did not deliver the survival benefit the agency expected.

Then

Merck withdrew the third-line gastric indication in the United States in 2021.

Now

The episode made tumor shrinkage an unreliable basis for gastric cancer approval and put the focus on survival endpoints.

Why this matters now

Merck is now leading with overall survival in the same disease, after losing an indication there five years ago.

2020-2024

TROP2 becomes a drug target (2020-2024)

Gilead's Trodelvy won accelerated approval in 2020 for triple-negative breast cancer, the first TROP2-directed antibody-drug conjugate on the US market. The class then stumbled: Trodelvy missed overall survival in a Phase 3 non-small cell lung cancer trial reported in January 2024.

Then

TROP2 conjugates stayed concentrated in breast and bladder cancer.

Now

The class kept expanding into new tumor types without a survival win outside breast cancer.

Why this matters now

TroFuse-015 is the first TROP2 conjugate to post an overall survival win in a global Phase 3 in gastroesophageal cancer, a disease where the class had no track record.

Sources

(7)